• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Thailand Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Thailand Pharmaceuticals and Healthcare Report Q1 2013

  • ID: 2356113
  • December 2012
  • Region: Thailand
  • 102 pages
  • Business Monitor International

FEATURED COMPANIES

  • Biolab
  • Company Profiles
  • Domestic Companies
  • GlaxoSmithKline (GSK)
  • Merck & Co
  • Multinational Companies
  • MORE

BMI View: The revival of the THB30 healthcare scheme in September 2012 will do little to ease the financial burden the government is facing as a result of the universal healthcare scheme. Nor will it solve existing issues such as the shortage of medical professionals and hospital overcrowding, given that these problems existed when the scheme was first implemented. We highlight that universal healthcare coverage will prove to be financially unsustainable in the long term, due to various factors –
including Thailand's ageing population (and therefore increased burden of non-communicable diseases),
medical tourism and the creation of the region-wide ASEAN Economic Community 2015 that is leading to the exit of medical professionals from Thailand’s public health sector.

Headline Expenditure Projections:

- Pharmaceuticals: THB130.95bn (US$4.41bn) in 2011 to THB136.34bn (US$4.18bn) in 2012;
+4.1% in local currency terms and -5.1% in US dollar terms. Forecast broadly unchanged from Q412.

- Healthcare: THB405.84bn (US$13.31bn) in 2011 to THB429.15bn (US$13.16bn) in 2012;
+5.7% in local currency terms and -1.1% in US dollar terms. Forecast broadly READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Biolab
  • Company Profiles
  • Domestic Companies
  • GlaxoSmithKline (GSK)
  • Merck & Co
  • Multinational Companies
  • MORE

Executive Summary 5

SWOT Analysis 7

Thailand Pharmaceutical And Healthcare Industry SWOT 7

Thailand Political SWOT 8

Thailand Economic SWOT 9

Thailand Business Environment SWOT 10

Pharmaceutical Risk/Reward Ratings 11
Table: Asia Pacific Pharmaceutical And Healthcare Risk/Reward Ratings, Q113 11

Rewards 12

Risks 12

Thailand – Market Summary 14

Regulatory Regime 16

Recent Regulatory Developments 17

Regional Harmonisation 18

Intellectual Property Regime 18

IP Shortcomings 19

Counterfeit Drugs 20

Compulsory Licensing 21

IP Developments 22

Pricing And Reimbursement 23
Table: Price Build-Up Of Medicines In Thailand 24

Industry Trends And Developments 25

Epidemiology 25

Communicable Diseases 26

Healthcare System 26

Healthcare Insurance 28
Table: Various Healthcare Scheme In Thailand 29

Medical Tourism 29

Research And Development (R&D) 31

Biosimilars 32

Clinical Trials 33

Medical Devices 35

Developments In The Medical Devices Sector 36

Industry Forecast Scenario 38

Overall Market Forecast 38
Table: Pharmaceutical Sales Indicators, 2008-2016 39

Healthcare Market Forecast 40
Table: Healthcare Expenditure Indicators, 2008-2016 41
Table: Healthcare Governmental Indicators, 2008-2016 41
Table: Healthcare Private Indicators, 2008-2016 42

Key Growth Factors – Macroeconomic 43

Thailand – Economic Activity 46

Prescription Drug Market Forecast 47
Table: Prescription Drug Sales Indicators, 2008-2016 48

Patented Drug Market Forecast 49
Table: Patented Drug Market Indicators, 2008-2016 50

Generic Drug Market Forecast 51
Table: Generic Drug Sales Indicators, 2008-2016 52

OTC Medicine Market Forecast 53
Table: OTC Medicine Sales Indicators, 2008-2016 54
Table: OTC Medicine Sales Indicators, 2008-2016 54

Pharmaceutical Trade Forecast 55
Table: Exports and Imports Indicators, 2008-2016 56

Medical Device Market Forecast 57
Table: Medical Devices Sales Indicators, 2008-2016 58

Other Healthcare Data 59

Key Risks To BMI’s Forecasts 60

Competitive Landscape 61

Pharmaceutical Industry 61

Domestic Pharmaceutical Industry 62
Table: Pharmaceutical Manufacturers Of Modern Drugs, 2007-2012 63
Table: Pharmaceutical Production At Wholesale Prices, 1983-2010 63

Foreign Pharmaceutical Industry 64
Table: PReMA Members, 2012 64

Recent Pharmaceutical Industry Developments 65

Pharmaceutical Wholesale 66

Pharmaceutical Retail 67
Table: Pharmacies By Region, 2000-09 68

Company Profiles 70

Domestic Companies 70

Siam Pharmaceutical 70

Government Pharmaceutical Organisation (GPO) 72

Biolab 75

Thai Meiji Pharmaceutical Company 77

Berlin Pharmaceutical Industry 79

Multinational Companies 81

Pfizer 81

Sanofi 83

GlaxoSmithKline (GSK) 86

Merck & Co 88

Novartis 90

Demographic Data 92

THAILAND – Population By Age Group 93

THAILAND – Population By Age Group 94

THAILAND – Key Population Ratios 95

THAILAND – Rural And Urban Population 95

Glossary 96

BMI Methodology 98

How We Generate Our Pharmaceutical Industry Forecasts 98

Pharmaceuticals Business Environment Ratings 99

Risk/Reward Ratings Methodology 99

Ratings Overview 99
Table: Pharmaceutical Business Environment Indicators 100

Weighting 101
Table: Weighting Of Components 101

Sources 101

Note: Product cover images may vary from those shown

Company Profiles
Domestic Companies
Siam Pharmaceutical
Government Pharmaceutical Organisation (GPO)
Biolab
Thai Meiji Pharmaceutical Company
Berlin Pharmaceutical Industry
Multinational Companies
Pfizer
Sanofi
GlaxoSmithKline (GSK)
Merck & Co
Novartis

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos